Advancing RNAi therapies globally to address significant cardiovascular risks

Sirius is an innovative biotech company developing novel RNAi therapies for global markets.

Innovative RNAi therapies for patients

Leveraging RNAi technology, our goal is to use an innovative medicine approach to offer new solutions for patients, which is changing the future of cardiovascular diseases.

Latest News

We have a world-class team with proven excellence

Our investors include OrbiMed, Creacion Ventures, Hankang Capital and Delos Capital, which are some of the world’s most renowned institutional investors who have a wealth of experience investing in the biopharmaceutical industry; while our leadership team, commanding a strong track record in translational medicine and drug development, comprises industry veterans who have previously served in senior positions at numerous world-leading multinational pharmaceutical companies, including Pfizer, AstraZeneca, Novartis, Arrowhead, Dicerna, and ONYX.

Sirius Therapeutics, Inc., all rights reserved

Privacy Policy|Contact Us